China Health Group

What China Health Group does

China Health Group Ltd. (08225.HK), previously known as Venturepharm (万全), is a Hong Kong-listed pharmaceutical technology and services company founded in 1998 with operational headquarters in Beijing and a regional office in Wan Chai, Hong Kong. The company operates an integrated platform built around Real World Studies (RWS), Real World Data (RWD) and AI, organized into three VP-led business units (VP-Tech Transfer, VP-PDS for drug development, and VP-CRO for clinical research) and four commercial service pillars: clinical research and evidence-based promotion (CHGRWS/CRSO), hospital management and Internet/eHospital托管 services, specialty clinics and telemedicine (including the CHGmyD RWS-THERAP model across allergy, psychiatry, stroke, addiction and rare disease), and rehabilitation and medical tourism programs in Hainan and Xiamen.

Its technology foundation rests on 7 proprietary VSmart® drug delivery platforms developed in-house and a portfolio of 100+ patents filed worldwide, supporting 300+ national new-drug preclinical studies completed since founding. The company monetizes through professional services and managed services contracts: clinical research and regulatory registration work for pharmaceutical clients, hospital operations consulting and ongoing management agreements with healthcare institutions, research-driven specialty care with telehealth and wearable monitoring, and project-based rehabilitation and medical tourism service packages. Pricing is quote-based and project-specific with no publicly disclosed tiers.

The customer base spans China Top-50 pharmaceutical companies plus global enterprise clients including GSK, Novartis and Alpharma, served through 8 global R&D centers across North America, Europe, Africa and Asia and a 400+ clinical site and field network. Go-to-market is direct enterprise B2B with dedicated account management and partnership inquiry handling, complemented by a bilingual corporate website and industry event participation. The company presents itself as a full-value-chain provider from API/formulation R&D through clinical execution and commercialization, but no revenue, headcount, or funding figures are disclosed in available source material.

Name

China Health Group

Legal name

China Health Group Ltd.

Website

https://chgi.net

Company type

Public

Founded year

1998

Operating status

Operating

Headcount range

11–50 employees

Short description

China Health Group (08225.HK) is a Hong Kong-listed, Beijing-headquartered pharmaceutical technology and services firm operating an RWS/RWD/AI-enabled platform for clinical research, hospital management, specialty telemedicine, and rehabilitation and medical tourism services for global and Chinese pharma clients.

Ownership category

akta.pro rank

Product category

Pharmaceutical & Healthcare Services

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Medical and Diagnostic Laboratories (62151), Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), General Medical and Surgical Hospitals (62211), Scientific Research and Development Services (5417)

SIC

Services-Health Services (8000), Services-Hospitals (8060), Pharmaceutical Preparations (2834), Services-Medical Laboratories (8071)

akta.pro primary industry

Real-World Evidence (RWE) & HEOR for Development (HLAIALAI)

akta.pro secondary industries

Real-World Data (RWD) / Real-World Evidence (RWE) & Observational Research Platforms (HLACAOAM), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), International/Medical Tourism Hospital Systems (HLAFAAAN), Specialty Care Pharmaceuticals (HLAIAAAB)

Keywords

• Clinical research services
• Hospital management
• Specialty healthcare
• Medical tourism
• Drug delivery platforms

Headquarters

HQ city

Haidian

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Research & Promotion Services: RWS-led clinical studies and evidence-based promotion (CRSO) connecting terminal clinics with market needs for compliant product growth. Includes research design, project execution, data analysis, and academic promotion support.
2. Hospital Management & eHospital托管 Services: Hospital operations management and mobile/eHospital management services including operational diagnostics, process optimization, SOP development, KPI systems, and digital operations support. Revenue generated through consulting fees and ongoing management service contracts.
3. Specialty Clinics & Telemedicine: Specialty care services in psych rehab, stroke/dementia, allergy, aesthetics & anti-aging combined with telehealth and wearable monitoring. Research-driven specialty services with ongoing patient management.
4. Rehabilitation & Medical Tourism: Rehab and med-tourism programs in Hainan and Xiamen regions. Services include project planning, resource integration, service package design, and operational standardization for sustainable healthcare ecosystems.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

China Health Group delivers clinical research, hospital management, specialty care/telemedicine, and rehabilitation/medical tourism services to pharmaceutical companies and healthcare institutions. Its offerings are powered by patented RWS/RWD/AI capabilities and seven proprietary VSmart® drug delivery platforms, covering the full pharmaceutical value chain from API/formulation R&D through clinical execution to market access.

Product overview

China Health Group operates as a new-drug technology and market services provider organized around four core pillars: (1) Clinical Research & Evidence — encompassing CHGRWS and CRSO services for real-world studies and evidence-based product promotion, anchored by 7 proprietary VSmart® drug-delivery platforms; (2) Hospital Management & eHospital Services — data-driven hospital operations and internet hospital management across multi-site networks; (3) Specialty Clinics & Telemedicine — research-driven specialty care in psychiatry, stroke/dementia, allergy, aesthetics, and rare disease, supported by wearable monitoring and the CHGmyD RWS-THERAP model; and (4) Rehab & Medical Tourism — rehabilitation and wellness-tourism programs in Hainan and Xiamen. The company also operates three VP-led business units (VP-Tech Transfer, VP-PDS for drug development, and VP-CRO for clinical research) to cover the full pharmaceutical value chain from API/formulation R&D through clinical execution and commercialization.

Differentiator

Problem solved

Functional benefit

Brands

• VSmart®: Proprietary drug-delivery platform system; 7 VSmart® platforms developed since 1998.

Products and services

• CHGRWS (Clinical Research & Real World Studies) RWS-led clinical research and evidence-based promotion (CRSO) service connecting terminal clinics and market needs to support product value evidence construction and compliant growth for pharmaceutical companies and medical institutions.
• Hospital Management & eHospital Services Hospital operations management and mobile/eHospital management services aimed at improving efficiency, quality, and patient experience across multi-site hospital networks, including internet hospital construction and compliance support.
• Specialty Clinics & Telemedicine Research-driven specialty clinical services covering psych rehab, stroke/dementia, allergy, aesthetics, and anti-aging, supported by telehealth and wearable monitoring to deliver integrated diagnosis and treatment.
• Rehab & Medical Tourism Rehabilitation and medical tourism programs in Hainan and Xiamen regions providing project planning, resource integration, service package design, and operational standardization for sustainable healthcare and wellness tourism.
• VSmart® Drug-Delivery Systems Proprietary drug-delivery technology platform consisting of 7 systems that support pharmaceutical innovation from lab to application across the pharmaceutical value chain.
• CHGmyD (Research-Type Specialty Model) Precision digital medical research-type specialty service model combining RWS, RWD, and AI to deliver integrated care from research to treatment (RWS-THERAP), covering allergy, psychiatry, stroke, addiction, and rare disease specialty brands.

Quantifiable outcome

• 300+ national new-drug preclinical studies completed
• +3 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Partnerships

Six partnerships are on record, tiered core.

• AlpharmacoreStrategic or Co-development PartnerGlobal pharmaceutical company partner receiving comprehensive R&D, clinical research, and regulatory registration services. The partnership supports Alpharma's product development and market expansion initiatives.
• GSKcoreStrategic or Co-development PartnerInternational pharmaceutical leader partnering for full-cycle R&D, clinical studies, and regulatory submission support across multiple therapeutic areas.
• NovartiscoreStrategic or Co-development PartnerGlobal pharmaceutical company receiving clinical research and regulatory registration services for drug development and market access in Asian markets.
• China Top-50 Pharmaceutical CompaniescoreStrategic or Co-development PartnerPartnership network serving China's leading pharmaceutical companies with comprehensive new drug technology development, clinical research, and market services.
• Hospitals and Healthcare InstitutionscoreStrategic or Co-development PartnerStrategic partnerships with general hospitals, specialty hospitals, and medical institution chains for operational management, digital transformation, and specialty care services.
• Rehabilitation Centers and Medical Tourism Projects (Hainan/Xiamen)coreStrategic or Co-development PartnerPartnerships with rehabilitation centers, healthcare parks, and medical tourism operators in Hainan and Xiamen for service design, operational standardization, and sustainable healthcare ecosystem development.

Scale indicators7 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Medpace Holdings: Mid-sized global CRO focused on Phase II-IV clinical development for biotech and pharma — overlaps with CHG's clinical research services.
• Asymchem Laboratories: China-based CDMO with API/formulation development and clinical supply — adjacent overlap with CHG's VP-PDS drug development and formulation capabilities.
• IQVIA: Global leader in clinical research, real world evidence, and healthcare analytics — the scale benchmark CHG's RWS/RWD/AI evidence-generation stack competes against.
• Charles River Laboratories: Global CRO with preclinical, clinical, and manufacturing services — comparable to CHG's preclinical (300+ studies) and clinical research operations.
• ICON plc: Global CRO providing clinical research, bioanalytical, and real world evidence services — competing for multinational pharma trial mandates.
• WuXi AppTec: Global China-headquartered CRO/CDMO with end-to-end discovery, development and manufacturing services — overlaps with CHG's VP-PDS drug development and clinical research offerings at larger scale.

Direct peers

• Hangzhou Tigermed: Leading China-based clinical CRO offering Phase I-IV clinical trial services, biostatistics, and regulatory support — directly comparable to CHG's CHGRWS / VP-CRO clinical research pillar.
• Pharmaron: China-based CRO/CDMO providing drug discovery, preclinical, CMC, and clinical research services — comparable service mix to CHG's integrated pharma services platform.

Regional players

• China Resources Medical Holdings: Hong Kong-listed hospital operator in China — comparable in the hospital management / clinical service delivery aspect of CHG's business.
• Genesis Healthcare: Asia-focused clinical CRO with Japan and China presence — comparable regional clinical trial delivery model to CHG's Asia-based R&D and clinical network.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about China Health Group